Idiopathic pulmonary fibrosis (IPF) is a highly lethal pathological process that is characterized by inflammation, fibroblast accumulation, and excessive collagen deposition. Although AKT2-mediated signaling pathways modulate inflammatory responses, their role in IPF has not been defined. We report that AKT2 deficiency () protected against bleomycin-induced pulmonary fibrosis and inflammation. Adoptive transfer of wild-type macrophages or administration of IL-13 to mice could restore pulmonary fibrosis. In response to IL-33 treatment, macrophages displayed decreased production of IL-13 and TGF-β1 and attenuated phosphorylation of FoxO3a compared with macrophages. Furthermore, the expression of IL-13 was increased by small interfering RNA knockdown of FoxO3a or in FoxO3a-deficient macrophages. By evaluating lung sections from pulmonary fibrosis patients, we found that the phosphorylation of AKT2 and FoxO3a was remarkably upregulated. Collectively, these results indicate that AKT2 modulates pulmonary fibrosis through inducing TGF-β1 and IL-13 production by macrophages, and inhibition of AKT2 may be a potential strategy for treating IPF.
Isoalantolactone (IAL) is a sesquiterpene lactone extracted from roots of Inula helenium L and has shown anti-inflammatory effects. In this study we investigated the therapeutic effects of IAL on acute lung injury (ALI) and elucidated the mechanisms underlying its anti-inflammation potential in vitro and in vivo. Treatment with lipopolysaccharide (LPS, 100 ng/mL) drastically stimulated production of inflammatory mediators such as NO, TNF-α, IL-1β, and IL-6 in mouse bone marrow-derived macrophages (BMDMs), which was dose-dependently suppressed by pretreatment with IAL (2.5, 5, 10, 20 μM). We further revealed that IAL suppressed LPS-induced NF-κB, ERK, and Akt activation. Moreover, the downregulation of non-degradable K63-linked polyubiquitination of TRAF6, an upstream transcription factor of NF-κB, contributed to the anti-inflammatory effects of IAL. ALI was induced in mice by intratracheal injection of LPS (5 mg/kg). Administration of IAL (20 mg/kg, i.p.) significantly suppressed pulmonary pathological changes, neutrophil infiltration, pulmonary permeability, and pro-inflammatory cytokine expression. Our results demonstrate that IAL is a potential therapeutic reagent against inflammation and ALI.
Gluconobacter oxydans is capable of rapidly incomplete oxidation of many sugars and alcohols, which means the strain has great potential for industrial purposes. Strong promoters are one of the essential factors that can improve strain performance by overexpression of specific genes. In this study, a pipeline for screening strong promoters by proteomics analysis was established. Based on the procedure, a new strong promoter designated as P B932_2000 was identified in G. oxydans WSH-003. The promoter region was characterized based on known genome sequence information using BPROM. The strength of P B932_2000 was further assessed by analysis of enhanced green fluorescent protein (egfp) expression and comparison with egfp expression by two commonly used strong promoters, P E. coli_tufB and P G. oxydans_tufB . Both quantitative real-time PCR and fluorescence intensities for egfp gene expression showed that P B932_2000 promoter is stronger than the other two. Overexpression of D-sorbitol dehydrogenase (sldh) by P B932_2000 in G. oxydans WSH-003 enhanced the titer and productivity of L-sorbose synthesis from D-sorbitol by 12.0 % and 33.3 %, respectively. These results showed that proteomics analysis is an efficient way to identify strong promoters. The isolated promoter P B932_2000 could further facilitate the metabolic engineering of G. oxydans.
Idiopathic pulmonary fibrosis is a progressive interstitial pneumonia
characterised by fibroblast accumulation, collagen deposition and extracellular
matrix (ECM) remodelling. It was reported that Akt1 mediated idiopathic
pulmonary fibrosis progression through regulating the apoptosis of alveolar
macrophage, while its effect on macrophage-produced cytokines remains largely
unknown. In the present study, we first examined the phosphorylation of Akt1 in
lung sections from idiopathic pulmonary fibrosis patients by
immunohistochemistry before applying a bleomycin-induced idiopathic pulmonary
fibrosis model using Akt1−/− mice and
Akt1+/+ littermates. The results showed that
Akt1 was remarkably up-regulated in idiopathic pulmonary fibrosis patients,
while in vivo studies revealed that Akt1-deficient mice had
well-preserved alveolar structure and fewer collagens, secreted fewer matrix
components, including alpha smooth-muscle actin and fibronectin and survived
significantly longer than Akt1+/+ littermates.
Additionally, the pro-fibrogenic cytokine IL-13 was down-regulated at least
twofold in Akt1−/−mice compared to the
Akt1+/+group on d 3 and 7 after bleomycin
treatment. Furthermore, it was found that Akt1–/– macrophages
displayed down-regulation of IL-13 compared to Akt1+/+ macrophages in
which Akt1 was phosphorylated in response to IL-33 stimulation. These findings
indicate that Akt1 modulates pulmonary fibrosis through inducing IL-13
production by macrophages, suggesting that targeting Akt1 may simultaneously
block the fibrogenic processes of idiopathic pulmonary fibrosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.